Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation-driven drug development in melanoma.

Current opinion in oncology - 1 May 2010

Flaherty Keith T, Hodi F Stephen, Bastian Boris C

Abstract excerpt

PURPOSE OF REVIEW: The identification of mutations in signal transduction pathways that are central in melanoma pathophysiology has provided new therapeutic targets for drug development. The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cutaneous Melanoma Detection and Management
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to Melanoma

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 20401974
DOI: 10.1097/cco.0b013e32833888ee
PMCID: PMC3107971

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20401974-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation-driven drug development in melanoma.PMID 20401974Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Targeted Therapy Innovations for Melanoma.Semantic proximity Read ↗

Driver mutations in melanoma: lessons learned from bench-to-bedside studies.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Melanoma in 2011: a new paradigm tumor for drug development.Semantic proximity Read ↗

Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Semantic proximity Read ↗

Evolution of Molecular Targets in Melanoma Treatment.Semantic proximity Read ↗

Targeted therapy for melanoma: a primer.Semantic proximity Read ↗

Molecularly targeted therapies for melanoma.Semantic proximity Read ↗

Advances in drug development. BRAF validation in melanoma.Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.